Financial Results Presentation for the Fiscal Year Ending March 2026

For the fiscal year ended March 2026, revenue increased 20.0% year on year, driven by the expansion of the home-visit pharmacy business, including new store openings. Operating profit, however, declined 22.3% due to costs associated with opening new facilities and lower per-resident fees. Compared with the previous assumptions, the revenue recognition for the Region Prime project was not approved, resulting in revenue and profit both falling short of plan.

Worth reading

76Important

Scored from 5 of 6 sections

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

Year-on-year change in net sales (%)

Wording

Conditional

How definitive the wording is.

No category-specific facts could be extracted from this document.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue benefited from an increase in the number of home-care patients accompanying the opening of new home-visit pharmacy stores. Operating profit was affected by the cost of opening the fourth Primary Care Home facility, lower per-resident fees at facilities including Kumamoto Hamasen, and opening and recruitment costs for the home-visit pharmacy business. Compared with the previous assumptions, the recognition of approximately ¥200 million in revenue from the Region Prime project was ultimately not approved.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.